Tirzepatide, explained
The drug behind Mounjaro and Zepbound hits two gut-hormone receptors instead of one, and the extra pathway shows up clearly in the numbers. What it is, what the trials showed, and what to watch for.
What it is and how it works
Tirzepatide is a single 39-amino-acid peptide that activates two receptors at once: GLP-1, the target semaglutide hits, and GIP, the other major incretin hormone. Like semaglutide it carries a fatty-acid modification that stretches its half-life to about a week, so it is taken as a once-weekly injection.
Why adding GIP helps is still argued over. GIP activation appears to improve insulin sensitivity and may soften the nausea that comes with GLP-1 activation, which in turn allows higher effective doses. Whether the benefit comes from the receptor itself or from better tolerability is an open question with a clear clinical answer either way. Doses start at 2.5 mg and step up every four weeks to a maximum of 15 mg, a ramp that takes about 20 weeks.
What the trials showed
Approved for type 2 diabetes in 2022 and for chronic weight management in 2023. In the obesity programme it produced the largest weight loss any approved drug has recorded, and unusually for this field it has been tested head-to-head against semaglutide rather than compared across trials.
Side effects, counterfeits and what happens when you stop
The side-effect profile mirrors semaglutide: dose-dependent nausea and vomiting, constipation, elevated gallbladder events, rare pancreatitis and the same thyroid C-cell warning from rodent studies. Skipping the 20-week ramp is the most reliable way to generate the gastrointestinal effects people then blame on the drug. Weight loss at this scale also takes lean mass unless protein intake and resistance training are managed deliberately.
Supply pressure has made tirzepatide one of the most counterfeited peptides in circulation. Regulators in several countries have documented fake pens containing insulin, and grey-market powder has repeatedly failed identity testing. As with semaglutide, most of the weight returns within a year of stopping, so this is a long-term medication where provenance and a monitoring prescriber matter more than squeezing out the last milligram.
Want the long version? Read the full tirzepatide write-up, with sources.
Research use only. A reading aid for the published literature, not medical advice. Talk to a licensed prescriber before starting or stopping any medication.